Hana Pharm Co Ltd
KRX:293480
Operating Margin
Hana Pharm Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
H
|
Hana Pharm Co Ltd
KRX:293480
|
190.5B KRW |
11%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
699.5B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
368.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.7B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.6B GBP |
23%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.3B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
206.3B USD |
36%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
11%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
119.8B EUR |
21%
|
Hana Pharm Co Ltd
Glance View
Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Hana Pharm Co Ltd's most recent financial statements, the company has Operating Margin of 11.2%.
You don't have any saved screeners yet